Table 11.
Commonly used chemotherapy and targeted therapy regimens for recurrent or metastatic breast cancer
| 1. Chemotherapy and targeted therapy regimens commonly used in HER2-negative breast cancer | |
| [1] Monotherapy | |
| Anthracyclines | |
| Doxorubicin 60–75 mg/m2 iv on day 1 | |
| 21 d/cycle | |
| or doxorubicin 20 mg/m2 iv once a week | |
| Epirubicin 60–90 mg/m2 iv on day 1 | |
| 21 d/cycle | |
| Liposomal doxorubicin 50 mg/m2 iv on day 1 | |
| 28 d/cycle | |
| Taxanes | |
| Paclitaxel 175 mg/m2 iv on day 1 | |
| 21 d/cycle | |
| or paclitaxel 80 mg/m2 iv once a week | |
| Docetaxel 60-100 mg/m2 iv on day 1 | |
| 21 d/cycle | |
| Nab-paclitaxel 100–150 mg/m2 iv on days 1, 8, and 15 | |
| 28 d/cycle | |
| or nab-paclitaxel 260 mg/m2 iv on day 1 | |
| 21 d/cycle | |
| Antimetabolites | |
| Capecitabine 1,000-1,250 mg/m2 po bid on days 1-14 | |
| 21 d/cycle | |
| Gemcitabine 800–1 200 mg/m2 iv on days 1, 8, and 15 | |
| 28 d/cycle | |
| Other microtubule inhibitors | |
| Vinorelbine 25 mg/m2 iv once a week or 50 mg po on days 1, 8, and 15 | |
| Eribulin 1.4 mg/m2 iv on days 1 and 8 | |
| 21 d/cycle | |
| Utidelone 30 mg/m2 iv on days 1-5 for a 21-d cycle | |
| Platinum-based drugs (for triple-negative breast cancer or breast cancer with known BRCA1/2 mutations) | |
| Cisplatin 75 mg/m2 iv on day 1 or 25 mg/m2 iv on days 1-3 | |
| 21 d/cycle | |
| Carboplatin AUC = 5–6 iv on day 1 | |
| 21–28 d/cycle | |
| PARP inhibitor (for breast cancer with known BRCA1/2 mutations; has not obtained indications in China yet) | |
| Olaparib 300 mg po bid | |
| Anti-TROP2 ADC (for triple-negative breast cancer; not yet approved for marketing in China) | |
| Sacituzumab govitecan-hziy 10 mg/kg iv on days 1 and 8 | |
| 21 d/cycle | |
| [2] Combination therapy | |
| XT regimen | |
| Docetaxel 75 mg/m2 iv on day 1 | |
| or nab-paclitaxel 100-150 mg/m2 iv on day 1 | |
| Once a week | |
| Capecitabine 1,000 mg/m2 po bid on days 1-14 | |
| 21 d/cycle | |
| GT regimen | |
| Paclitaxel 175 mg/m2 iv on day 1 | |
| Gemcitabine 1,000–1,250 mg/m2 iv on days 1 and 8 | |
| 21 d/cycle | |
| NX regimen | |
| Vinorelbine 25 mg/m2 iv on days 1 and 8 or 40 mg po on days 1, 8, and 15 | |
| Capecitabine 1,000 mg/m2 po bid on days 1-14 | |
| 21 d/cycle | |
| GP regimen (for triple-negative breast cancer) | |
| Gemcitabine 1,000–1,250 mg/m2 iv on days 1 and 8 | |
| Cisplatin 75 mg/m2 iv on day 1 or 25 mg/m2 iv on days 1-3 | |
| 21 d/cycle | |
| GC regimen (for triple-negative breast cancer) | |
| Gemcitabine 1,000 mg/m2 iv on days 1 and 8 | |
| Carboplatin AUC = 2 iv on days 1 and 8 | |
| 21 d/cycle | |
| AP regimen (for triple-negative breast cancer) | |
| Nab-paclitaxel 125 mg/m2 iv on days 1 and 8 | |
| Cisplatin 75 mg/m2 iv on day 1 or 25 mg/m2 iv on days 1-3 | |
| 21 d/cycle | |
| NP regimen (for triple-negative breast cancer) | |
| Vinorelbine 25 mg/m2 iv on days 1 and 8 | |
| Cisplatin 75 mg/m2 iv on day 1 or 25 mg/m2 iv on days 1-3 | |
| Or carboplatin AUC = 2 iv on days 1 and 8 | |
| 21 d/cycle | |
| PC regimen | |
| Paclitaxel 175 mg/m2 iv on day 1 | |
| or nab-paclitaxel 125 mg/m2 iv on days 1 and 8 | |
| Carboplatin AUC = 5–6 day 1, or AUC = 2 iv on days 1 and 8 | |
| 21 d/cycle | |
| Paclitaxel + bevacizumab (bevacizumab has not yet been approved for indications in China) | |
| Paclitaxel 90 mg/m2 iv on day 1, 8, and 15 | |
| Bevacizumab 10 mg/kg days 1 and 15 | |
| 28 d/cycle | |
| Immunotherapy regimens containing PD-1/PD-L1 antibody (can be used for triple-negative breast cancer, but their indications have not yet been approved in China) | |
| ① Atezolizumab + nab-paclitaxel (when PD-L1 SP142 is positive, i.e., IC ≥ 1%) | |
| Atezolizumab 840 mg iv on days 1, 15 | |
| Nab-paclitaxel 100 mg/m2 iv on days 1, 8, and 15 | |
| 28 d/cycle | |
| ② Pembrolizumab + chemotherapy (when PD-L1 22C3 CPS ≥ 10) | |
| Pembrolizumab 200 mg iv on day 1, 21 d/cycle | |
| Nab-paclitaxel 100 mg/m2 iv on days 1, 8, and 15 | |
| 28 d/cycle | |
| Or paclitaxel 90 mg/m2 iv on days 1, 8, and 15; 28 d/cycle | |
| Or gemcitabine 1,000 mg/m2 iv on the 1st day + carboplatin AUC = 2 iv on days 1 and 8; 21 d/cycle | |
| 2. Chemotherapy and targeted therapy regimens commonly used in HER2-positive breast cancer | |
| THP regimen | |
| Docetaxel 75 mg/m2 iv on day 1 | |
| Or nab-paclitaxel 100-150 mg/m2 iv once a week on day 1 | |
| or paclitaxel 80 mg/m2 iv once a week on day 1 | |
| Trastuzumab first dose of 8 mg/kg followed by 6 mg/kg iv on day 1 | |
| Pertuzumab first dose 840 mg, followed by 420 mg iv on day 1 | |
| 21 d/cycle | |
| TXH regimen | |
| Docetaxel 75 mg/m2 iv on day 1 | |
| Capecitabine 1,000 mg/m2 po bid on days 1-14 | |
| Trastuzumab (with a first dose of 8 mg/kg) followed by 6 mg/kg iv on day 1 | |
| 21 d/cycle | |
| TH regimen | |
| Nab-paclitaxel 100-150 mg/m2 iv on day 1 | |
| Trastuzumab (with a first dose of 4 mg/kg) followed by 2 mg/kg iv on day 1 | |
| 7 d/cycle | |
| or | |
| Docetaxel 75 mg/m2 iv on day 1 | |
| Trastuzumab (with a first dose of 8 mg/kg) followed by 6 mg/kg iv on day 1 | |
| 21 d/cycle | |
| NH Regimen | |
| Vinorelbine 30 mg/m2 iv on days 1 and 8 | |
| Trastuzumab (with a first dose of 4 mg/kg) followed by 2 mg/kg iv on day 1 | |
| 21d/cycle | |
| or | |
| Vinorelbine 25 mg/m2 iv on days 1, 8, and 15 | |
| Trastuzumab or inetetamab (with a first dose of 4 mg/kg) followed by 2 mg/kg iv on day 1 | |
| 28 d/cycle | |
| XH regimen | |
| Capecitabine 1,000-1,250 mg/m2 po bid on days 1-14 | |
| Trastuzumab (with a first dose of 8 mg/kg) followed by 6 mg/kg iv on day 1 | |
| 21 d/cycle | |
| PCbH | |
| Paclitaxel 175 mg/m2 iv on day 1 | |
| or nab-paclitaxel 125 mg/m2 iv on days 1 and 8 | |
| Carboplatin AUC = 5–6 day 1, or AUC = 2 iv on days 1 and 8 | |
| Trastuzumab (with a first dose of 8 mg/kg) followed by 6 mg/kg iv on day 1 | |
| 21 d/cycle | |
| Pyrotinib + capecitabine regimen | |
| Pyrotinib 400 mg po qd | |
| Capecitabine 1,000 mg/m2 po bid on days 1-14 | |
| 21 d/cycle | |
| Neratinib + capecitabine regimen | |
| Neratinib 240 mg po qd on days 1-21 | |
| Capecitabine 750 mg/m2 po bid on days 1-14 | |
| 21 d/cycle | |
| Lapatinib + capecitabine | |
| Lapatinib 1,250 mg po qd | |
| Capecitabine 1,000 mg/m2 po bid on days 1-14 | |
| 21 d/cycle | |
| Lapatinib + Trastuzumab | |
| Lapatinib 1,000 mg po qd | |
| Trastuzumab (with a first dose of 8 mg/kg) followed by 6 mg/kg iv on day 1 | |
| 21 d/cycle | |
| T-DM1 monotherapy | |
| 3.6 mg/kg iv on day 1 | |
| 21 d/cycle | |
| DS8201 (has not been approved for use in China yet) | |
| 5.4 mg/kg iv on day 1 | |
| 21 d/cycle |